Johnson & Johnson subsidiary Biosense Webster has received the approval to launch its Thermocool Smarttouch SF Catheter in the US to treat drug resistant paroxysmal atrial fibrillation (Afib).

It is based on direct contact force technology and provides uniform cooling while easing the fluid management process.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Thermocool Smarttouch Catheter allows physicians the ability to create a stable application of contact force by providing direct, quantitative feedback in real time, which is displayed on the Carto 3 System monitor upon tissue contact

"The Thermocool Smarttouch SF Catheter represents a significant advancement for the clinical community."

The catheter tip is fitted with a sensor which allows direct measurement of contact force applied on heart tissue.

The contact force reading is then transmitted through a coil to the Carto 3 System which creates real-time 3D maps of the heart during the minimally invasive catheter ablation procedures.

See Also:

The device features a spring which moves to respond to contact force providing calculation in grams.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

St David's Medical Centre Texas Cardiac Arrhythmia Institute executive medical director Dr Andrea Natale said: "The Thermocool Smarttouch SF Catheter represents a significant advancement for the clinical community.

"Conducted trials, including the Smart -AF and Smart-SF studies, have shown Biosense Webster technology enables physicians to achieve targeted stability in the defined contact force range, leading to shorter procedure times and enhanced results without compromising safety."

The recent Smart-AF trial of the catheter has suggested its safety while treating drug refractory paroxysmal atrial fibrillation also resulting to reduction in procedure time.